JamesBrufauBrugarolasMDPhD
Oncology • Dallas, TXGenitourinary Oncology, Hematologic Oncology
Director, Kidney Cancer Program; Sherry Wigley Crow Endowed Chair in Cancer Research; Professor of Internal Medicine/ Hematology-Oncology, Cancer Biology, Genetics, Development and Disease at UT Southwestern Medical Center
Dr. Brugarolas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5323 Harry Hines Blvd
Dallas, TX 75390Phone+1 214-648-4059- Is this information wrong?
Summary
Clinical Expertise
- Kidney Neoplasms, Renal cell carcinoma, Urologic oncology, Hematologic oncology
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2003
Duke University HospitalResidency, Internal Medicine, 1998 - 2001
Massachusetts Institute of TechnologyPhD, Biology, 1993 - 1998
Universidad de Navarra Faculty of MedicineClass of 1993
Certifications & Licensure
TX State Medical License 2006 - 2024
MA State Medical License 2002 - 2007
NC State Medical License 1998 - 2004- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Principal Investigator, Kidney Cancer Specialized Program of Research Excellence (SPORE) National Cancer Institute
- Elected to the American Society for Clinical Investigation 2013
- Individual Investigator Research Award Cancer Prevention and Research Institute of Texas, 2010
- Join now to see all
Publications & Presentations
PubMed
- Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.Raquibul Hannan, Mark F McLaughlin, Laurentiu M Pop, Ivan Pedrosa, Payal Kapur, Aurelie Garant, Chul Ahn, Alana Christie, James Zhu, Tao Wang, Liliana Robles, Deniz Du...> ;European Urology. 2023 Mar 8
- 2 citationsIn vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma.Akash K Kaushik, Amy Tarangelo, Lindsey K Boroughs, Mukundan Ragavan, Yuanyuan Zhang, Cheng-Yang Wu, Xiangyi Li, Kristen Ahumada, Jui-Chung Chiang, Vanina T Tcheuyap, ...> ;Science Advances. 2022 Dec 16
- HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans.Yuanqing Ma, Allison Joyce, Olivia Brandenburg, Faeze Saatchi, Christina Stevens, Vanina Toffessi Tcheuyap, Alana Christie, Quyen N Do, Oluwatomilade Fatunde, Alyssa M...> ;Clinical Cancer Research. 2022 Dec 15
- Join now to see all
Press Mentions
Stereotactic Radiation Highly Effective for Kidney CancerMay 2nd, 2017
UT Southwestern Finds Determining Factor in Kidney Cancer AggressivenessAugust 14th, 2017
Findings Establish PT2385 as a Highly Specific HIF-2 Inhibitor for Patients with Clear Cell RCCFebruary 27th, 2020- Join now to see all
Grant Support
- Specialized Program of Research Excellence (SPORE)NIH/NCI2016–Present
Committees
- Chair, Scientific Advisory Board, National Kidney Cancer Academy 2020 - Present
- Chair, Congressionally Directed Medical Research Program – Kidney Cancer Research Program 2017 - 2018
Professional Memberships
- Member
- Member
- American Society for Clinical Investigation - ASCIMember
Other Languages
- Spanish
Hospital Affiliations
University of Texas Southwestern Medical CenterDallas, Texas
External Links
- Kidney Cancer Programhttp://www.utsouthwestern.edu/kidneycancer
- Brugarolas Labhttp://www3.utsouthwestern.edu/brugarolaslab
- Kidney Cancer SPOREhttps://trp.cancer.gov/spores/kidney.htm
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
